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Abstract
Background: Hepatocellular carcinoma (HCC) is a lethal malignancy with high rate of metastasis
and poor prognosis. There are no effective managements to block metastasis of HCC. Programmed
cell death 4 (PDCD4) is found to be a tumor transformation suppressor. Among investigations on
effects of PDCD4, little is about the metastatic potentials of HCC cells. This study was to
investigate the role of PDCD4 on metastatic potential of human HCC cells.
Methods:  We examined the expression of PDCD4 in three HCC cell lines with different
metastatic potentials, MHCC-97H (high metastatic potential), MHCC-97L (low metastatic
potential) and Hep3B (no metastatic potential). A plasmid encoding PDCD4 gene was constructed
and then transfected into HCC cells with the lowest PDCD4 expression level. Effects of PDCD4
on cell proliferation, cell apoptosis, gene expression of metastasis tumor antigen 1 (MTA1) and in
vitro migration and invasion capacity were assessed after transfection.
Results: Our results showed that the expression level of PDCD4 was inversely correlated to the
metastatic potential of HCC cells. After transfection with the PDCD4 gene, HCC cell proliferation
rate was significantly decreased, cell apoptosis rate was significantly increased, the expression of
MTA1 gene, HCC cell migration and Matrigel invasion were also remarkably inhibited.
Conclusion: PDCD4 expression is inversely correlated to the metastatic potential of HCC cells.
PDCD4 can effectively suppress the metastatic potential of HCC cells.
Introduction
Hepatocellular carcinoma (HCC) is a frequent and lethal
malignancy with high rate of metastasis, especially in
some regions of Africa and Asia [1]. It ranks the sixth most
common cancer of men and 11th one of women world-
wide. There were more than half a million deaths per year.
The number of new HCC cases occurring each year is
almost equivalent to the number of deaths [2,3]. Since
HCC is clinically silent at early stage, most HCC patients
(> 80%) are presented with advanced or unresectable dis-
ease. Without treatment, the 5-year survival rate of HCC is
less than 5%. To those with resected disease, the recur-
rence rate can be as high as 50% at 2 years and the 5 year
survival rate is only 25–39%. Despite of the advances in
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treatment, the prognosis of HCC remains very poor due to
the frequent presence of recurrence and the high rate of
metastasis [3-5].
The programmed cell death 4 (PDCD4) was found to be
an inhibitor of neoplastic transformation. It was first
found to be highly expressed during apoptosis, but the
role of PDCD4 in programmed cell death was not clear. A
comparative study on cells with different transformation
response to tumor promoters revealed that PDCD4 was
expressed more than ten folds higher in promotion-sensi-
tive cells than in promotion-resistant cells. In less pro-
gressed mouse keratinocytes, higher level of PDCD4 was
expressed [6]. Later investigations demonstrated that loss
of PDCD4 expression was associated with tumor progres-
sion in carcinomas of the lung, colon, prostate, and breast
[7]. The inhibition of PDCD4 on transformation is
achieved through down-regulation of the JNK signal
transduction pathway which is essential for cell migra-
tion. Decrease of JNK activity then leads to inhibition of
cell migration [8,9].
The metastasis tumor antigen 1 (MTA1) was originally
identified by differential expression in rat mammary ade-
nocarcinoma metastatic cells [10]. The expression of the
MTA1 gene was found to be positively correlated with
metastatic potential of some human cell lines and tissues,
such as the breast, prostate, colon and pancreas [11-13].
More and more researches on the effects of PDCD4 have
been performed, among which little is about the relation
of PDCD4 to metastatic potentials of HCC cells. Based on
the previous studies, we hypothesized that PDCD4 might
also play a role on the inhibition of HCC metastasis. To
testify this hypothesis, we first examined the expressions
of PDCD4 in three human HCC cell lines with different
metastasis potentials, then we transfected a plasmid
encoding the PDCD4 gene into HCC cells with lowest
PDCD4 expression level and further investigated the
effects of PDCD4 on the gene expression of MTA1 and
migration and invasion of HCC cells.
Methods
Cell lines and cell culture
Three human HCC cell lines, MHCC-97H (high meta-
static potential), MHCC-97L (low metastatic potential),
Hep3B(no metastatic potential) [14], were obtained from
the Liver Cancer Institute of Zhongshan Hospital, Fudan
University, Shanghai, China. One normal human liver
cell line L02 [15]and one mouse fibroblast cell line
NIH3T3[16] was obtained from the Central Laboratory of
Shandong Provincial Hospital. HCC cells were routinely
cultured in Dulbecco's modified Eagle's medium
(DMEM) with high glucose (Hyclone, USA). L02 and
NIH3T3 cells were cultured in RPMI 1640 medium
(Hyclone, USA). Both the DMEM and the RPMI 1640
medium were supplemented with 10% fetal bovine serum
(FBS, Gibco, USA), antibiotics (100 U/ml penicillin, 2 μg/
ml streptomycin) and 2 mmol/L glutamine, at 37°C in a
humidified, 5% CO2 atmosphere.
Immunocytochemistry
MHCC-97H, MHCC-97L and Hep3B cells were cultured
in 24-well plates with one glass slide in each well. Twenty
four hours later, the slides were washed with PBS, fixed
with 4% paraformaldehyde for 30 min and permeablized
with 0.2% Triton X-100 for 20 minutes. In order to inhibit
the endogenous peroxidase activity, the slides were treated
with 3% H2O2 for 15 min. The nonspecific binding sites
were blocked by incubation in a solution of 5% bovine
serum albumin (BSA) for 20 min. The primary rabbit pol-
yclonal antibody to PDCD4 (Santa Cruz Biotechnology,
Santa Cruz, California, USA. diluted by 1:30 in phos-
phate-buffered saline, PBS) was applied and incubated at
4°C, overnight. Slides were washed twice with PBS and
incubated with biotinylated goat anti-rabbit IgG (Santa
Cruz Biotechnology, Santa Cruz, California, USA) at a
1:100 dilution. Slides were then incubated for 30 min
with HRP-conjugated streptavidin (Zhongshan Biotech-
nology, Beijing, China). The avidin/biotin complexes
were revealed with a diaminobenzidine (DAB) kit
(Zhongshan Biotechnology, Beijing, China) according to
the manufacturer's instructions. Hematoxylin was used to
counterstain the slides which were then dehydrated and
cover-slipped. Equal volume of PBS was used instead of
the primary antibody and served as a negative control
[17].
A semi-quantitative scoring method was used to assess the
expression level of PDCD4. The histological score
(HSCORE) was calculated with the following equation:
HSCORE = ΣPi (i+1), where i = intensity of staining with
a value of 1, 2, 3 or 4 (weak, moderate, strong or very
strong, respectively) and Pi is the percentage of stained
cells for each intensity grade, varying from 0 to 100%. In
each slide, five different areas were evaluated under a
microscope with 200-fold original magnification, the per-
centage of the cells for each intensity grade within these
areas was determined by two investigators at different
times, and the average score was used[18].
RNA isolation and real-time PCR
Total RNAs of MHCC-97H, MHCC-97L or Hep3B cells
were extracted by Trizol (Invitrogen) reagent and 0.5 μg of
each kind of RNA was reversely transcripted into first-
strand cDNA with the RT reagent kit (Takara, Dalian,
China) according to the manufacturer's protocol. Real-
time quantitative PCR was performed with a QuantiTect
SYBR Green kit (TaKaRa, Dalian, China) in a 10 μl reac-
tion volume, which contained 5 μl of SYBR® Green I PCRJournal of Experimental & Clinical Cancer Research 2009, 28:71 http://www.jeccr.com/content/28/1/71
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mix, 0.2 μM of forward and reverse primer, 1 μl of diluted
cDNA template, and appropriate amounts of sterile
ddH2O. Conditions for PCR of the other molecules were
as follows: 5 min at 95°C; 40 cycles of 15 s at 95°C and
60 s at 60°C; 15 s at 95°C and 15 s at 60°C. The entire
experiments were repeated at least three times. All quanti-
fications were performed with human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as an internal stand-
ard. Primer sequences used in the PCR were as follows:
PDCD4: 5'-CAGTTGGTGGGCCAGTTTATTG-3' (sense),
5'-AGAAGCACGGTAGCCTTATCCA-3' (antisense);
MTA1: 5'-AAGCACGCAACCCTGTCAGTC-3' (sense), 5'-
TCTCGGGCAGGTCCACCATTT-3' (antisense); GAPDH:
5'-ACAGCGACACCCACTCCTCC-3' (sense), 5'-
TAGCCAAATTCGTTGTCATACCAG-3' (antisense). Real-
time PCR was carried out on an ABI PRISM 7500
Sequence Detection System (Applied Biosystems, NJ,
USA), and results were analyzed using the integrated
Sequence Detection System Software Version 1.4. The rel-
ative quantification (RQ) of gene expression was analyzed
by the 2-ΔΔCt method and the results were expressed as
extent of change with respect to control values [19].
Plasmid construction
RNA was isolated from the L02 cells using Trizol reagent
(Invitrogen). The RT reagent kit (Jingmei Biotech, Shen-
zhen, China) was used to transcript RNA into cDNA
according to the manufacturer's instructions. The whole
coding sequence of human PDCD4 gene (Genbank acces-
sion no. [BC026104.2]) was amplified by polymerase
chain reaction (PCR) with primers: 5'-CTCTAGAATGGAT-
GTAGAAAATGAGCAG-3' (154–174) (sense), and 5'-
GCGGTACCTCAGTAGCTCTCTGGTTTAAG-3' (1563-
1543) (antisense). The XbaI and EcoRI restriction sites
were introduced to the primers, respectively. The final vol-
ume of reaction was 80 μl, containing 1 μl (≤ 1 μg) of
cDNA mixture, 10 × PCR buffer 8 μl, 1.0 μl of each dNTP,
0.5 μl of Taq polymerase, 1.0 μl of each PDCD4 gene
primer. The PCR amplification was performed for 35
cycles as follows: at 95°C for 2 min, at 90°C for 30 s, at
56°C for 30 s, and at 72°C for 90 s, with a final extension
at 72°C for 10 min. The PCR product was digested by
KpnI and subcloned into EcoRI and XbaI sites of the
pcDNA3.1 (-) vector (Invitrogen) to generate pcDNA3.1 (-
)-PDCD4 construct. The recombinant was identified by
double digestion with restriction enzymes and DNA
sequencing was performed by Shanghai Sangon Biologi-
cal Engineering Technology and Service Co. Ltd (Sangon).
Cell transfection
In order to study the effects of PDCD4, we transfected the
pcDNA3.1 (-)-PDCD4 plasmid into MHCC-97H cells
which was shown to express lowest level of PDCD4. Cells
were grown to 70% confluence in 6-well plates,
pcDNA3.1 (-)-PDCD4 plasmid (2 μg per well) was trans-
fected by LipofectAMINE 2000 (Invitrogen) according to
the manufacturer's instructions. The empty vector
pcDNA3.1 (-) was also transfected as a control. The paren-
tal cells without transfection were considered to be
another control group. Stable clones were generated by
selection in complete culture medium containing 400 μg/
mL G418 48 h later. Western blot analysis was taken to
identify the effectiveness of the PDCD4 transfection[20].
Western blot analysis
Western blot analyses were performed to detect the
expression of PDCD4, to identify the effectiveness of the
PDCD4 gene transfection and to analyze the expression of
MTA1 after PDCD4 transfection. HCC cells grown to 70–
90% confluence were washed with ice-cold PBS for two
times and then collected by scraping. The cell pellets were
homogenized in extraction buffer (50 mM Tris-HCl, 0.1%
SDS, 150 mM NaCl, 100 μg/ml phenylmethylsulfonyl flu-
oride, 1 μg/ml aprotinin, 1% Nonidet P-40, and 0.5%
sodium orthovanadate), then incubated at 4°C for 30
min and centrifuged 20 min at 12,000 g/min. The total
proteins (50 μg per lane) were resolved in 10% SDS-poly-
crylamide gels, and then transferred onto nitrocellulose
membrane (0.45 μm, Millipore, Bedford, MA, USA) in 25
mM Tris-base, 190 mM glycine, and 20% methanol using
a semi-dry blotter. Following blocking with 10% nonfat
milk and 0.1% Tween20 in TBS for 2 h, the membranes
were incubated with anti-PDCD4(Santa Cruz Biotechnol-
ogy, Santa Cruz, California, USA, 1:200 for gene expres-
sion and 1:2000 for identification of transfection), anti-
MTA1(Santa Cruz Biotechnology, Santa Cruz, California,
USA, 1:500) or anti-β-actin (Jingmei Biotech, Shenzhen,
China, 1:2000), respectively, at 4°C overnight. After bind-
ing of horseradish peroxidase (HRP)-coupled goat anti-
mouse or goat anti-rabbit IgG (Jingmei Biotech, Shen-
zhen, China,1:5000) at room temperature for 2 h, anti-
gens were visualized by enhanced chemiluminescence
(Santa Cruz Biotechnology, Santa Cruz, California, USA,)
Bands corresponding to different proteins were scanned
and the respective areas and IOD were determined using
Image-Pro Plus 6.0. The relative densities were calculated
by normalizing the IOD of each blot with that of β-actin
[21].
MTT assay for cell proliferation
Cell proliferation rates of MHCC-97H-PDCD4, MHCC-
97H-vector and MHCC-97H cells were evaluated with 3-
(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium
bromide (MTT) assay. An equal number of cells (5 × 103)
from the different stable cell lines of MHCC-97H-PDCD4
(Group 1), MHCC-97H-vector (Group 2) and MHCC-
97H (Group 3) were seeded in triplicate with serum-con-
taining medium in six 96-well plates. At 0–5 day of cul-
ture, MTT assay was performed daily using one plate. The
medium was replaced with 100 μl of fresh serum-freeJournal of Experimental & Clinical Cancer Research 2009, 28:71 http://www.jeccr.com/content/28/1/71
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medium containing 20 μl each time. The cells were incu-
bated at 37°C for an additional 4 h. After the removal of
the medium, 100 μl of dimethyl sulfoxide (DMSO) was
added, and the formation of colored formazan dye was
assessed at 490 nm. The experiment was was repeated 3
times [22].
Cell cycle analysis
The cell cycle distribution of MHCC-97H cells was
assessed based on their DNA contents and detected by the
DNA Reagent Kit (Beckman Coulter, Fullerton, California,
USA), according to the manufacturer's protocol. Twenty-
four hours after transient transfection, MHCC-97H cells
were trypsinized, washed with PBS, suspended in 100 μl
PBS and fixed with 70% alcohol for 30 minutes on ice.
Cells were then washed with cold PBS twice and resus-
pended in hypotonic solution [0.1% sodium citrate, 0.2%
Nonidet P-40 (NP-40)] and then incubated with 50 μg/
mL propidium iodide and 0.25 mg/mL RNase A at 4°C for
30 min in the dark. After incubation at 37°C for further 15
min, the DNA contents were analyzed on a flow cytometry
(Beckman-Coulter, Fullerton, California, USA) [23].
According to the DNA contents, the percentage of G1, S
and G2 were determined. PI was then calculated as fol-
lows: PI = (S+G2)/(S+G2+G1) [24].
Flow cytometric assay for cell apoptosis
Flow cytometry was used to evaluate cell apoptosis 24
hours after transient transfection. According to the manu-
facturer's instructions, the MHCC-97H cells undergoing
apoptosis were determined by the Annexin V-FITC/PI
apoptosis assay kit (Jingmei Biotech, Shenzhen, China).
The cells were trypsinized, washed with PBS, suspended in
100 μl PBS and fixed with 70% alcohol for 30 minutes on
ice. Cells were then washed with cold PBS twice, resus-
pended in ice-cold binding buffer and incubated with
Annexin V-FITC and PI for 10 min prior to flow cytometry
analysis[25].
Hoechst 33258 staining for apoptotic morphology
Hoechst 33258 staining was performed 24 h after transit
transfection. MHCC-97H cells were stained with Hoechst
33258 (5 μg/ml, Sigma) for 10 min at room temperature
in the dark, washed three times with PBS and analyzed
with a fluorescence microscope. At least 200 cells were
counted and the percentage of apoptotic cells were calcu-
lated[26].
Migration and Matrigel invasion assay
Cell migration and invasion tests were performed in Tran-
swell chambers (Corning Coster; Cambridge, MA)
equipped with a filter membrane with 8-μm pores, coated
with(for invasion assay) or without(for migration assay)
50 μg Matrigel (Sigma). Fibroblast conditioned medium
(NIH3T3-CM), containing a mixture of molecules and
capable of stimulating the migration of invasive cells, was
used as chemoattractant in these experiments [27].
MHCC-97H-PDCD4, MHCC-97H-vector or MHCC-97H
cells were suspended in 100 μl DMEM containing 10%
FBS and plated at 1 × 105 cells/well onto the upper com-
partment of the chamber. The lower chambers were filled
with 600 μl NIH3T3-CM, which was obtained by a 24 h
incubation of NIH3T3 cells with 50 μg/ml ascorbic acid in
serum-free DEME media [16]. Cells were cultured at 37°C
in a humidified, 5% CO2 atmosphere for another 24
hours. The filters were then washed with PBS, fixed with
95% methanol for 20 min and stained with hematoxylin
and eosin solution. Cells on the upper surface of the filters
were gently removed with cotton swabs. The number of
cells that had migrated to the lower surface of the filter
membrane was counted in five randomly chosen fields
under a light microscope (× 200). The average number of
migrated cells per microscopic field was analyzed[28].
Statistical Analyses
Data were reported as means ± SD of the combined exper-
iments. Student's two-tailed t test for independent means
was employed to determine significant differences (P <
0.05). Analyses were performed using SPSS16.0 statistical
program.
Results
Expression of PDCD4
The expression of PDCD4 in three different metastatic
potential HCC cell lines was detected. The positive immu-
nocytochemical staining for PDCD4 was brownish and
localized in cytoplasm (Fig. 1A). HSCORE for MHCC-
97H cells, MHCC-97L cells and Hep3B cells was 0.85 ±
0.17, 1.46 ± 0.36 and 1.97 ± 0.29, respectively (Fig. 1B).
Difference between Group1 and Group2 (n = 5, P < 0.05)
or Group1 and Group3 (n = 5, P < 0.01) or Group2 and
Group3 (n = 5, P < 0.05) was significant.
The quantitative assay by real time PCR was reported in
RQ units as compared with the noninvasive Hep3B cells
(Fig. 1C). RQ for MHCC-97H cells and MHCC-97L cells
was 0.126 ± 0.023 and 0.385 ± 0.084, respectively. The
mean RQ for Group1 and Group2 was 0.126 ± 0.023 and
0.385 ± 0.084, respectively. The difference between
Group1 and Group2 was significant (n = 3, P < 0.05).
Western blots for PDCD4 expression display a band of 54
kD (Fig. 1D). The relative densities (RD) of PDCD4 for
Group1, Group2 and Group3 were 0.053 ± 0.045, 0.268
± 0.067 and 0.587 ± 0.182, respectively (Fig. 1E). Differ-
ence between Group1 and Group2 or Group1 and
Group3 was significant (n = 3, P < 0.05). There is no dif-
ference between Group2 and Group3 (n = 3, P > 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:71 http://www.jeccr.com/content/28/1/71
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Expression of PDCD4 in HCC cells Figure 1
Expression of PDCD4 in HCC cells. A: Immunocytochemical staining. The positive staining(×200) was brownish and local-
ized in cytoplasm. D: Western blot assay. Representative figures are shown from one of three individual experiments. B, C or 
E shows statistical analysis for immunocytochemical staining, real – time PCR or western blot assay, respectively. In A, a, b or c 
represents cells of MHCC-97H, MHCC-97L or Hep3B, respectively; d shows cell staining without the primary antibody. In B, C 
and E, Group1, Group 2 or Group3 represents cells of MHCC-97H, MHCC-97L and Hep3B, respectively. Bars represent the 
means ± SD. The difference between Group1 and Group2 (P < 0.05) or Group1 and Group3 (P < 0.01 in B; P < 0.05 in E) was 
significant.Journal of Experimental & Clinical Cancer Research 2009, 28:71 http://www.jeccr.com/content/28/1/71
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Data of the above experiments showed that the highest
metastatic potential MHCC-97H cells expressed lowest
level of PDCD4. The expression level of PDCD4 was
inversely correlated with the metastasis potentials of HCC
cells.
Plasmid construction and efficiency of PDCD4 
transfection
A plasmid pcDNA3.1 (-)-PDCD4 encoding the PDCD4
gene was constructed. The recombinant was identified by
double digestion with restriction enzymes and sequenc-
ing analysis. DNA sequencing of the recombinant
pcDNA3.1 (-)-PDCD4 was also identified by Sangon. The
efficiency of PDCD4 gene transfection was identified by
western blot analysis (Fig. 2A).
Effects of PDCD4 on MHCC-97H cells proliferation
The MHCC-97H cell proliferation rate was assayed by
MTT. The detected absorbance at 490 nm of the MHCC-
97H-PDCD4 group was 0.543 ± 0.150, which was lower
than that of the MHCC-97H-vector group (1.343 ± 0.268)
or MHCC-97H group (1.278 ± 0.258). The difference was
significant (n = 3, P < 0.05). No statistical difference was
found between the two control groups (n = 3, P > 0.05)
(Fig. 2B).
To further testify the effect of PDCD4 on proliferation of
HCC cells, cell cycle analysis with a flow cytometer was
performed and the proliferative indexes (PI) were calcu-
lated. As shown in Table 1, an increase of percentage both
in G1 stage and in G2 stage was observed in MHCC-97H-
PDCD4 cells, accompanied by a corresponding reduction
in the percentage of cells in S phase. PI was 27.83 ± 0.95%,
42.47 ± 2.90% and 44.47 ± 2.37% for the MHCC-97H-
PDCD4 cells, the MHCC-97H-vector and the MHCC-97H
cells, respectively. The difference of G1, G2, or S percent-
age and PI between the MHCC-97H-PDCD4 cells and the
MHCC-97H-vector or the MHCC-97H cells is significant
(n = 3, P < 0.05). No significant difference was found
between the MHCC-97H-vector and the MHCC-97H
cells. These data indicate that PDCD4 might promote
both G1 and G2 arrest in MHCC-97H cells and further
block the proliferation of HCC cells.
Effects of PDCD4 on MHCC-97H cell apoptosis
Cell apoptosis was analyzed both quantitatively and mor-
phologically. The apoptosis rate detected by the flow cyto-
metric assay was 13.03 ± 1.47%, 2.99 ± 0.33% and 2.47 ±
0.15% in the MHCC-97H -PDCD4 cells (Group1), the
MHCC-97H-vector cells (Group2) and the MHCC-97H
cells (Group3), respectively (Fig. 2C).
Hoechst 33258 staining showed the nuclear alterations of
apoptosis – condensed, coalesced, and segmented nuclei
with a brighter blue fluorescence. The percentage of apop-
tosis cells was 29.84 ± 3.80% in MHCC-97H -PDCD4
group(Group1), 5.666 ± 0.44% in the MHCC-97H-vector
group (Group2) and 4.62 ± 0.43% in the MHCC-97H
group (Group3), respectively. (Fig. 2D). The difference
was significant between Group1 and Group2 or Group3
(n = 5, P < 0.01). There was no statistical difference
between the two control groups.
Effects of PDCD4 on MTA1 expression of MHCC-97H cells
In order to further study the effects of PDCD4 on metas-
tasis, we detected the gene expression of MTA1 in MHCC-
97H-PDCD4, MHCC-97H-vector and MHCC-97H cells,
respectively, with both real- time PCR and western blot-
ting analysis. The quantitative assay of real- time PCR was
reported in RQ units as compared with the parental
MHCC-97H cells. RQ for the recombinant group and the
empty vector group was 0.187 ± 0.083 and 0.652 ± 0.105,
respectively. The difference was significant (n = 3, P <
0.05) (Fig. 3A). Western blots for PDCD4 expression dis-
play a band of 80 kD (Fig. 3B). The relative densities (RD)
of MTA1 for MHCC-97H cells, MHCC-97L cells and
Hep3B cells were 0.074 ± 0.047, 0.376 ± 0.045 and 0.395
± 0.069, respectively (Fig. 3C). The difference was signifi-
cant (n = 3, P < 0.05).
Effects of PDCD4 on MHCC-97H cell migration and 
invasion
In the migration assay, the average number of migrated
cells per field of the MHCC-97H -PDCD4 group (Group1)
was 27.20 ± 7.26, which was much lower than that of the
MHCC-97H -vector group (Group2) (161.80 ± 17.06) or
the MHCC-97H group (Group3) (194.60 ± 30.83) (Fig.
3D). The average number of migrated cells in the invasion
assay was 19.0 ± 3.18, 64.40 ± 9.61 and 69.80 ± 12.32 for
the Group1, Group2 and Group3, respectively (Fig. 3E).
The difference was significant between Group1 and
Group2 or Group3 (n = 5, P < 0.01). There is no difference
between Group2 and Group3.
Discussion
PDCD4 was originally found to be an apoptosis-associ-
ated gene in mouse cells. PDCD4 expression was found to
be up-regulated in cells treated with various apoptosis-
inducing agents such as topoisomerase inhibitors, corti-
costeroids and cytokine deprivation[29]. The function of
PDCD4 in the course of programmed cell death remains
unclear. Later studies showed that PDCD4 was a suppres-
sor of tumor cell transformation. The expression levels of
PDCD4 were reduced in many human progressed carcino-
mas[7]. A study on human HCC showed that expression
level of PDCD4 protein was much lower in HCC tissues
tested than that of the corresponding noncancerous
liver[30].Journal of Experimental & Clinical Cancer Research 2009, 28:71 http://www.jeccr.com/content/28/1/71
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Effects of PDCD4 on MHCC-97H cell proliferation and apoptosis Figure 2
Effects of PDCD4 on MHCC-97H cell proliferation and apoptosis. A: Western blot analysis for identification of trans-
fection efficiency. B: MTT assay for cell proliferation. C: Flow cytometric assay for cell apoptosis. D: Hoechst 33258 staining for 
cell apoptosis (×200). Morphological changes of cell apoptosis were shown as chromatin condensation and nuclear fragmenta-
tion. Representative images are shown from three individual experiments. In C and D, a or Group1, b or Group 2, and c or 
Group3 represents cells of MHCC-97H-PDCD4, MHCC-97H-vector and MHCC-97H, respectively; d shows statistical analysis 
for each assay. Bars represent the means ± SD. The difference between Group1 and Group2 or Group3 was significant (P < 
0.01).Journal of Experimental & Clinical Cancer Research 2009, 28:71 http://www.jeccr.com/content/28/1/71
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In this study, we showed that higher metastatic potential
HCC cells expressed lower level of PDCD4. The expres-
sion levels of PDCD4 were inversely correlated with the
metastasis potentials of HCC cells. This result is consistent
with the previous findings. We also demonstrated that the
MHCC-97H cell proliferation rate was remarkably
decreased and the cell apoptosis rate was significantly
increased after transfection with the PDCD4 gene. Cell
cycle analysis showed that transfection of PDCD4 gene
increase the percentage of both G1 and G2. Data of our
results suggest that PDCD4 might promote cell cycle arrest
in phase of G1 and in G2 and further block the cell prolif-
eration. It is known that PDCD4 is a binding partner of
the eukaryotic translation initiation factor 4A (eIF4A). By
binding to eIF4A, PDCD4 can directly inhibit translation
initiation and then delay the process of protein synthesis.
A study on Bon-1 carcinoid cells showed that PDCD4 not
only suppressed the transcription of the mitosis-promot-
ing factor cyclin-dependent kinase 1(CDK1)/cdc2, but
also decreased the expression of CDK4/6[31]. CDK1 and
CDK4/6 are are directly involved in cell cycle control.
Decrease of CDK1 or CDK4/6 promotes cell cycle arrest in
G1 or G2 phase and further inhibits proliferation of
cells[32].
PDCD4 inhibits the activity of c-Jun N-terminal kinase
(JNK), blocks the JNK signaling pathway and conse-
quently decreases the activation of c-Jun and AP-1-
dependent transcription[8]. Many genes regulated by AP-
1 are important modulators of invasion and metastasis.
Decrease of expression or inhibition of activation of AP-1
results in inhibition of tumor cell motility and invasive-
ness[33].
Our study revealed that the expression of the MTA1gene
was remarkably decreased after the PDCD4 gene transfec-
tion. In the migration and Matrigel invasion assay, we dis-
covered that the MHCC-97H cells migrated to the lower
surface were greatly decreased after PDCD4 gene transfec-
tion. A study on a human acute myeloid leukemia (AML)
cell line NB4 demonstrated that Knockdown of PDCD4
by RNA interference (siRNA) leads to induction of c-myc,
suggesting that c-myc maybe a potential down-stream tar-
get of PDCD4[7]. MTA1 is an integral subunit of nucleo-
some remodeling and histone deacetylation (NuRD)
complex which contains both histone deacetylase and
nucleosome remodeling activity. It has been shown to be
overexpressed in metastatic carcinomas. Recent studies on
rat fibroblasts cells revealed that MTA1 is one of the essen-
tial first down-stream effectors of the c-myc oncoprotein.
Activation of c-myc causes induction of the MTA1 expres-
sion [34]. In MHCC-97H cells stably transfected with the
PDCD4, activity of c-myc maybe inhibited and the gene
expression of MTA1 is further blocked.
Metastasis is a multistep process. Cell migration and inva-
sion are essential for tumor progression and metastasis.
Matrigel is a reconstituted basal membrane with most
components of extracellular membrane. Malignant cells
have to degrade the surrounding ECM before spread [35].
Metastatic potential of MHCC-97H cells had been found
to be correlated to the number of cells migrated in the
migration and invasion assay [14].
In summary, we showed that the expression of PDCD4
was inversely correlated to the metastatic potentials of
HCC cells. PDCD4 effectively blocked the proliferation
rate, decreased the gene expression of metastasis associ-
ated protein1, and inhibited the migration and invasion
activities of MHCC-97H cells. These results demonstrate
that PDCD4 might be a novel suppressor to metastatic
potential of HCC cells. By our knowledge, this was the
Table 1: Data of effect of PDCD4 on MHCC-97H cell cycle distribution
Cell line phase of cell PI
G1 S G2
MHCC-97H-PDCD4 70.83 ± 3.53 23.50 ± 0.20 5.50 ± 0.58 29.05 ± 0.28
MHCC-97H-vector 67.33 ± 1.02 31.13 ± 0.44 1.90 ± 0.45 32.98 ± 0.89
MHCC-97H 67.43 ± 0.75 30.63 ± 0.98 1.93 ± 0.47 32.57 ± 0.75
The cell-cycle distribution was assessed by flow cytometric analysis 24 h after
transfection of PDCD4 to MHCC-97H cells. The data shown are means ± SEM of percentage of G1, G2 or S phase in three experiments. The 
proliferative indexes (PI) were calculated as follows: PI = (S+G2)/(S+G2+G1). The difference of PI between the MHCC-97H-PDCD4 group and 
MHCC-97H-vector or the MHCC-97H group is significant (n = 3, P < 0.05). No significant difference between the MHCC-97H-vector and the 
MHCC-97H group is found.Journal of Experimental & Clinical Cancer Research 2009, 28:71 http://www.jeccr.com/content/28/1/71
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Effects of PDCD4 on MHCC-97H cell metastatic potential Figure 3
Effects of PDCD4 on MHCC-97H cell metastatic potential. B: Western blots for MTA1 expression. A and C: Statistical 
analysis for MTA1 expression with real-time PCR and western blot assay, respectively. D: Cell migration assay. E: Matrigel inva-
sion assay. Representative images are shown from three individual experiments. In A, C, D and E, a or Group1, b or Group 2, 
and c or Group3 represents cells of MHCC-97H-PDCD4, MHCC-97H-vector and MHCC-97H, respectively. Bars represent 
the means ± SD. Difference between Group1 and Group2 or Group1 and Group3 was significant (P < 0.05 in A and C; P < 
0.01 in D and E).Journal of Experimental & Clinical Cancer Research 2009, 28:71 http://www.jeccr.com/content/28/1/71
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first observation to investigate the effects of PDCD4 on
metastatic potential of HCC cells. Further studies are
required to confirm these findings in vivo.
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